ACell Names CEO

Columbia, Md.-based ACell Inc. has named Patrick McBrayer president and CEO. McBrayer succeeds Kyle Kerbawy, who will remain as chairman of the board.

McBrayer has more than 20 years of healthcare senior management experience. He currently serves on the board of directors of Misonix Inc. and was president and CEO of AxioMed Spine Corporation until the company was acquired in 2014.

“Pat has strong executive experience in regulated healthcare environments, a track record of maximizing the potential of early-stage technology, and a proven commitment to improving patient care,” said Kerbawy. “the board is confident that he will be a transformational CEO for ACell as he leads our next phase of growth and innovation.”

“ACell’s pioneering technology has immense potential to help people in a wide range of therapeutic areas,” said McBrayer. “I am honored to assume this leadership role, and look forward to working with our board of directors, management, and employee teams to advance ACell’s current strategic priorities and develop new opportunities for growth.”

Prior to AxioMed, McBrayer was CEO of Xylos Corporation, a medical biomaterials company. He was also a founder of Transave Inc. (now Insmed Inc.), a biotechnology company focused on the site specific treatment of lung disease. Prior to joining Xylos, McBrayer served as president and CEO of Exogen Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew Inc. in 1999.

Previously, McBrayer was President and CEO of Osteotech Inc., a tissue technology company (acquired by Medtronic plc). He has been responsible for a number of private placements, as well as Osteotech and Exogen’s public offerings. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, McBrayer held positions of increasing responsibility for Johnson & Johnson Inc.

He has over 20 years healthcare senior management experience and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. McBrayer is a graduate of the United States Military Academy at West Point.

ACell is a regenerative medicine company focused on the development, manufacturing and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues.